SYRE
Price
$32.94
Change
-$0.11 (-0.33%)
Updated
Dec 26 closing price
Capitalization
2.56B
61 days until earnings call
Intraday BUY SELL Signals
VKTX
Price
$37.18
Change
-$0.17 (-0.46%)
Updated
Dec 26 closing price
Capitalization
4.2B
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SYRE vs VKTX

Header iconSYRE vs VKTX Comparison
Open Charts SYRE vs VKTXBanner chart's image
Spyre Therapeutics
Price$32.94
Change-$0.11 (-0.33%)
Volume$307.91K
Capitalization2.56B
Viking Therapeutics
Price$37.18
Change-$0.17 (-0.46%)
Volume$1.63M
Capitalization4.2B
SYRE vs VKTX Comparison Chart in %
SYRE
Daily Signal:
Gain/Loss:
VKTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
SYRE vs. VKTX commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Buy and VKTX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (SYRE: $32.94 vs. VKTX: $37.18)
Brand notoriety: SYRE and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 39% vs. VKTX: 47%
Market capitalization -- SYRE: $2.56B vs. VKTX: $4.2B
SYRE [@Biotechnology] is valued at $2.56B. VKTX’s [@Biotechnology] market capitalization is $4.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, VKTX is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 3 TA indicator(s) are bullish while VKTX’s TA Score has 5 bullish TA indicator(s).

  • SYRE’s TA Score: 3 bullish, 5 bearish.
  • VKTX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, VKTX is a better buy in the short-term than SYRE.

Price Growth

SYRE (@Biotechnology) experienced а -1.38% price change this week, while VKTX (@Biotechnology) price change was +5.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

SYRE is expected to report earnings on Feb 26, 2026.

VKTX is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VKTX($4.2B) has a higher market cap than SYRE($2.56B). SYRE YTD gains are higher at: 41.495 vs. VKTX (-7.604). SYRE has higher annual earnings (EBITDA): -223.64M vs. VKTX (-274.4M). VKTX has more cash in the bank: 715M vs. SYRE (486M). SYRE has less debt than VKTX: SYRE (0) vs VKTX (755K). SYRE (0) and VKTX (0) have equivalent revenues.
SYREVKTXSYRE / VKTX
Capitalization2.56B4.2B61%
EBITDA-223.64M-274.4M82%
Gain YTD41.495-7.604-546%
P/E Ratio1.72N/A-
Revenue00-
Total Cash486M715M68%
Total Debt0755K-
FUNDAMENTALS RATINGS
SYRE vs VKTX: Fundamental Ratings
SYRE
VKTX
OUTLOOK RATING
1..100
6265
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
3641
P/E GROWTH RATING
1..100
80100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (38) in the Biotechnology industry is in the same range as SYRE (70) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to SYRE’s over the last 12 months.

VKTX's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to SYRE’s over the last 12 months.

VKTX's SMR Rating (96) in the Biotechnology industry is in the same range as SYRE (97) in the Pharmaceuticals Major industry. This means that VKTX’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as VKTX (41) in the Biotechnology industry. This means that SYRE’s stock grew similarly to VKTX’s over the last 12 months.

SYRE's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as VKTX (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYREVKTX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
85%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 4 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
SYRE
Daily Signal:
Gain/Loss:
VKTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TIOVX16.710.07
+0.42%
Nuveen International Opps W
MMPDX34.340.04
+0.12%
NYLI WMC Value Class R6
COIIX17.970.02
+0.11%
Calvert International Opportunities I
ESGIX18.130.02
+0.11%
Dana Epiphany Equity Inst
LGRRX29.95-0.02
-0.07%
Loomis Sayles Growth A

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with XNCR. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-0.33%
XNCR - SYRE
57%
Loosely correlated
-1.49%
RGNX - SYRE
57%
Loosely correlated
-2.07%
BEAM - SYRE
57%
Loosely correlated
-0.57%
CGON - SYRE
56%
Loosely correlated
-0.75%
APGE - SYRE
56%
Loosely correlated
-0.99%
More

VKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VKTX has been loosely correlated with NEVPF. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VKTX jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VKTX
1D Price
Change %
VKTX100%
-0.46%
NEVPF - VKTX
45%
Loosely correlated
N/A
SYRE - VKTX
44%
Loosely correlated
-0.33%
IMTX - VKTX
41%
Loosely correlated
-1.45%
RGNX - VKTX
40%
Loosely correlated
-2.07%
BEAM - VKTX
40%
Loosely correlated
-0.57%
More